PHILADELPHIA--(BUSINESS WIRE)-- Imvax, a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, announced the appointment of Josh Muntner as the company’s chief financial officer effective August 31, 2021.

“We are proud to further bolster our leadership team with the appointment of Josh, who brings to Imvax significant expertise in areas of capital markets and fundraising which will be instrumental to our continued trajectory of growth,” said John P. Furey, CEO of Imvax. “I also want to express my profound thanks to Art Howe, co-founder of Imvax and outgoing CFO, for his tireless efforts building the company over the years. We are at a point of exciting momentum as we progress clinical development of IGV-001 and look to expand our platform to address other solid tumors.”

Mr. Muntner has more than 20 years of experience in healthcare investment banking and corporate finance, and he has played a lead role in a wide range of healthcare-related transactions. Most recently, he served as chief financial officer at Mesoblast Limited (ASX: MSB) (Nasdaq: MESO), a late-stage biotechnology company, from May 2018. From 2015 to 2018, Mr. Muntner served as senior vice president of business development at ContraFect Corporation (Nasdaq: CFRX), a biotechnology company. From 2012 to 2015, Mr. Muntner served as managing director and co-head of healthcare investment banking at Janney Montgomery Scott, and, before that, spent nine years at Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets. Mr. Muntner holds a BFA from Carnegie Mellon University and an MBA from the Anderson School of Management at the University of California, Los Angeles.

“I’m excited to join Imvax in this period of expansion of the company’s therapeutic platform and realization of its clinical potential,” said Mr. Muntner. “Imvax’s platform technology has shown immense promise, and I look forward to working with the team to bring these novel therapies to patients.”

About Imvax, Inc.

Imvax is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax is headquartered in Philadelphia, PA. For additional information, please visit www.imvax.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005089/en/